MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...

SAN FRANCISCO -- Despite a growing emphasis on quality-of-life (QoL) endpoints and patient-reported outcomes in cancer trials ...

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $47.18, with a high estimate of $54.00 and a low estimate of $35.00. Surpassing the previous ...

The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, ...

In a statement to Sir Keir Starmer, the MP said she had taken the decision to step down from her ministerial responsibilities to focus on representing the people of West Lancashire.

In a statement to Sir Keir Starmer, the MP said she had taken the decision to step down from her ministerial responsibilities to focus ...

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...

Twenty peak patient bodies will join the Royal Australian College of GPs (RACGP) in Parliament House today to tell Australia's leaders that patients ...

Twenty peak patient bodies will join the Royal Australian College of GPs (RACGP) in Parliament House today to tell Australia's leaders that patients ...

Biohaven Ltd. (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range ...